AJMC March 11, 2022
Expectations regarding the future utilization of comprehensive genomic profiling in clinical practice to assess patients with solid tumor cancers.
Bruce Feinberg, DO: We’re going to shift gears and talk about the future of genomic profiling. And get back to my original question: Are we at an inflection point? Is complete genomic profiling, has it moved from the last thing you do when you’ve exhausted standard of care to the first thing you do before you initiate systemic therapy? And that would be in the metastatic setting or at all.
Mark, it sounds like certainly in terms of thoracic medical oncology, if it’s reflex testing at a pathologic level, it has moved into being the first thing you do that guides...
Today's Sponsors
Today's Sponsor